RNA: The Forgotten Molecule That Controls Everything And Is Now Rewriting Medicine

When people think about the molecular basis of life, they think about DNA. The double helix. The blueprint. The molecule that carries your genetic information from your parents to you, and from you to your children. DNA gets the credit, the textbook diagrams, the Nobel Prizes in the popular imagination.

RNA barely gets a mention. It is usually described, if described at all, as a kind of molecular middleman — a temporary copy of DNA that carries instructions to the protein-making machinery. A courier. A means to an end.

This picture is wrong. Not incomplete — genuinely wrong. RNA is not a passive messenger. It is one of the most versatile, consequential, and biologically active molecules in nature. It regulates which genes are expressed and when. It catalyses the chemical reactions that build every protein in your body. It may have been the original molecule of life — appearing billions of years before DNA existed. It has been quietly running vast portions of the cellular machinery while DNA took all the credit.

And in the last decade, the realisation of what RNA actually does has triggered one of the most productive periods in the history of medicine. The mRNA vaccines that protected hundreds of millions of people during the COVID-19 pandemic. The RNA interference drugs now treating diseases that were previously incurable. The circular RNA therapies entering clinical trials. The long non-coding RNAs whose disruption underpins cancer, neurodegeneration, and heart disease.

This is the story of RNA — what it actually is, what it actually does, where it came from, and where the RNA revolution is taking medicine next.

What RNA Is — and How It Differs from DNA

RNA — ribonucleic acid — is a close chemical relative of DNA. Like DNA, it is a polymer built from nucleotides, each carrying one of four nitrogen-containing bases. Like DNA, it encodes information in the sequence of those bases. Like DNA, it folds into specific three-dimensional structures that determine its function.

But three chemical differences make RNA fundamentally distinct from DNA — and those differences explain almost everything about what RNA can do that DNA cannot.

The first difference is the sugar. DNA uses deoxyribose — a sugar that lacks a hydroxyl group at the 2′ position of the ring. RNA uses ribose, which has that hydroxyl group. This small chemical difference makes RNA less stable than DNA — it is more vulnerable to hydrolysis, to enzymatic degradation, to spontaneous breakdown. DNA’s stability makes it an ideal long-term archive. RNA’s relative instability makes it ideal for dynamic, responsive, short-lived molecular signals — messages that can be sent, read, and quickly cleared.

The second difference is a single base. Where DNA uses thymine (T), RNA uses uracil (U). Uracil pairs with adenine exactly as thymine does, so the information content is equivalent. The difference is metabolic — thymine requires an extra chemical synthesis step to produce, which may reflect evolutionary constraints on where each molecule appeared first.

The third and most consequential difference is structure. DNA is almost always double-stranded — its stability and information-storage function depend on the complementary base pairing that holds the two strands together. RNA is mostly single-stranded. But a single-stranded molecule can fold back on itself, forming hairpins, loops, bulges, and complex three-dimensional structures through internal base pairing. This folding capacity is what gives RNA its extraordinary functional versatility. A single RNA molecule can carry genetic information, fold into a specific three-dimensional structure, and use that structure to catalyse a chemical reaction — all three at once. No other known biological molecule can do all of this.

The Many Lives of RNA: A Family Portrait

RNA is not a single molecule. It is a large and diverse family of molecules, each with distinct structure, function, and biology. Understanding what RNA actually does requires meeting the family.

Messenger RNA (mRNA) is the most familiar member — the molecule that carries the genetic message from the DNA in the nucleus to the ribosomes in the cytoplasm, where proteins are assembled. Each mRNA is a single-stranded copy of a gene, produced by RNA polymerase reading the DNA template in a process called transcription. The mRNA is then translated by ribosomes into the corresponding protein. mRNA molecules are deliberately transient — they are produced when a protein is needed and degraded when it is not, allowing gene expression to be rapidly adjusted in response to changing conditions. The average human mRNA has a half-life of hours to days, though this varies enormously between different transcripts.

Ribosomal RNA (rRNA) is the most abundant RNA in any cell — it makes up roughly 80% of total cellular RNA. Ribosomal RNA forms the core of the ribosome, the molecular machine that translates mRNA into protein. The critical discovery that changed biology’s understanding of ribosomes — and of RNA more broadly — came from structural studies of the ribosome in the late 1990s and early 2000s.

Researchers including Thomas Steitz, Ada Yonath, and Venkatraman Ramakrishnan, who shared the 2009 Nobel Prize in Chemistry, showed through X-ray crystallography that the catalytic centre of the ribosome — the site where peptide bonds are actually formed — is made entirely of RNA, not protein. The ribosome is a ribozyme. Proteins in the ribosome are structural scaffolding. The chemistry of life — the assembly of every protein in every organism on Earth — is catalysed by RNA.

Transfer RNA (tRNA) is the molecular adapter that translates the language of nucleic acids into the language of proteins. Each tRNA carries a specific amino acid and has a specific anticodon sequence — a three-base sequence that pairs with the corresponding codon on the mRNA. When a ribosome reads a codon, the tRNA carrying the matching amino acid docks at the ribosome, the amino acid is added to the growing protein chain, and the tRNA departs to pick up another amino acid. There are 61 different sense codons and approximately 45 tRNA species in the human cell, with some tRNAs serving multiple codons through a phenomenon called wobble base pairing.

Small nuclear RNA (snRNA) is a component of the spliceosome — the molecular machine that removes introns (non-coding sequences) from pre-mRNA and joins the remaining exons together to produce the final mature mRNA. This process, called RNA splicing, is universal in eukaryotic cells and can occur in different ways for different transcripts — alternative splicing allows a single gene to produce multiple different proteins, enormously expanding the protein-coding capacity of the genome without requiring additional genes. It is estimated that over 95% of human multi-exon genes undergo alternative splicing.

The Non-Coding Revolution: When Scientists Realised 98% of RNA Wasn’t Junk

For decades after the central dogma was established, the working assumption was that the important RNAs were the ones that carried protein-coding information — mRNAs — and the structural components of ribosomes and the translation machinery. The vast majority of the genome, which did not code for proteins, was assumed to produce little of consequence — junk DNA making junk RNA.

That assumption has been demolished comprehensively in the past two decades. We are now in the RNA revolution, propelled by the realisation that genes determine phenotype beyond the foundational central dogma — over 95% of the human genome is transcribed into RNA, and the vast majority of those transcripts are non-coding. They do not make proteins. But they are not inert. They are doing something. And what they are doing is turning out to be fundamental to virtually every aspect of cell biology.

MicroRNAs (miRNAs) are short RNA molecules, typically 21 to 23 nucleotides long, that bind to complementary sequences in target mRNAs and either direct their degradation or suppress their translation into protein. Discovered in the roundworm C. elegans in 1993 by Victor Ambros and Gary Ruvkun — who shared the 2024 Nobel Prize in Physiology or Medicine for this discovery — miRNAs have since been found in virtually every multicellular organism studied. The human genome encodes over 2,000 miRNA genes, and each miRNA can regulate hundreds of different target mRNAs. Together, miRNAs are thought to regulate the expression of the majority of human protein-coding genes. Their disruption is implicated in cancer, cardiovascular disease, neurological disorders, and metabolic disease.

Long non-coding RNAs (lncRNAs) are RNA molecules longer than 200 nucleotides that do not encode proteins. The human genome encodes over 50,000 lncRNA genes — more than twice the number of protein-coding genes — though the functions of most remain poorly characterised. Those that have been studied reveal extraordinarily diverse biology. XIST, perhaps the best-characterised lncRNA, coats one of the two X chromosomes in female cells and orchestrates its compaction into an inactive structure called the Barr body — the mechanism by which females silence one of their two X chromosomes to equalise gene dosage with males.

HOTAIR recruits chromatin-modifying complexes to specific genomic locations, silencing gene expression in a manner that is dysregulated in multiple cancers. NEAT1 is a structural component of nuclear condensates called paraspeckles, involved in retaining specific RNAs in the nucleus during cellular stress. The emerging picture is that lncRNAs are the cell’s master regulators of genome organisation — scaffolding the three-dimensional architecture of chromatin, recruiting epigenetic modifiers, and coordinating gene expression programmes across vast genomic distances.

Circular RNAs (circRNAs) are a recently discovered class of RNA molecules that, unlike all previously described RNAs, form covalently closed circular structures with no free ends. They are extraordinarily stable — their circular topology protects them from the degradation enzymes that destroy linear RNA — and they are abundant in neurons and other long-lived cell types. Some circRNAs function as “sponges” that sequester specific miRNAs, preventing them from silencing their target genes. Others interact with RNA-binding proteins or are translated into proteins. Their stability and abundance in body fluids including blood and cerebrospinal fluid make them promising biomarkers for disease, including neurodegeneration and cancer.

The RNA World: Where Life Began

RNA’s versatility — its ability to both carry genetic information and catalyse chemical reactions — has a profound implication for the origin of life. Modern cells use three distinct types of molecule: DNA to store genetic information, RNA to carry it, and proteins to catalyse reactions. The interdependence of these three systems raises an obvious question: which came first? You need proteins to replicate DNA, but you need DNA to make proteins. The system cannot have bootstrapped itself from scratch.

The RNA world hypothesis, named by the Nobel laureate Walter Gilbert in 1986, proposes a resolution: RNA came first. Before DNA, before proteins, there was RNA — molecules that could store genetic information and catalyse chemical reactions simultaneously. In the prebiotic environment of early Earth, RNA molecules that could replicate themselves and catalyse useful chemistry would have been subject to natural selection, gradually evolving greater complexity and efficiency. DNA eventually superseded RNA as the genetic archive — more stable, less susceptible to hydrolysis — and proteins took over most catalytic functions from ribozymes, leaving RNA in its current intermediary role.

The evidence for the RNA world is substantial and growing. The ribosome — the universal protein-synthesis machine — is a ribozyme, catalysing the most fundamental reaction in all of cell biology. Many essential metabolic cofactors, including ATP, NADH, and Coenzyme A, are nucleotide-based or contain nucleoside moieties, consistent with the hypothesis that they are molecular fossils of an RNA-based metabolism. And ribozymes — catalytic RNA molecules — can in principle carry out a wide variety of chemical reactions, as demonstrated through laboratory evolution experiments.

The most direct support has come from the Salk Institute for Biological Studies, where Gerald Joyce’s group has spent a decade engineering increasingly capable RNA polymerase ribozymes — RNA molecules that can make copies of other RNA strands. In a landmark 2024 study, his team developed an RNA polymerase ribozyme capable of replicating other functional RNA molecules with sufficient accuracy that Darwinian evolution could occur — mutations arose, beneficial variants were selected, and the population adapted. “This study suggests the dawn of evolution could have been very early and very simple,” said first author Nikolaos Papastavrou.

“We’ve long wondered how simple life was at its beginning and when it gained the ability to start improving itself.” The experiment did not create life, but it demonstrated that the core feature of life — self-replicating molecules subject to natural selection — is possible with RNA alone, without DNA or protein.

A February 2026 feature in Chemistry World reviewing recent advances in prebiotic chemistry noted that the discovery that the ribosome is a ribozyme, along with the versatility of RNA, provides strong evidence that RNA pre-dated both DNA and proteins in the evolution of life, and that recent work in prebiotic chemistry suggests many of life’s essential building blocks could have arisen together from simple molecules such as hydrogen cyanide, enabling the emergence of RNA-based protocells without stepwise assembly.

The mRNA Revolution: From COVID Vaccines to Cancer Cures

The most widely publicised RNA story of the past decade is the development of mRNA vaccines. But the full scope of what mRNA technology is becoming extends far beyond COVID-19, and the science behind it is more remarkable than the headlines convey.

The central idea of mRNA medicine is straightforward: instead of delivering a drug directly, deliver the genetic instructions for the cell to make the drug itself. An mRNA molecule encoding a therapeutic protein — an antigen for vaccination, an enzyme for replacing a missing one, a cytokine for cancer immunotherapy — is packaged into lipid nanoparticles that protect it from degradation and carry it into cells, where it is translated into the therapeutic protein. The mRNA is then degraded by normal cellular mechanisms, leaving no permanent genetic changes.

The intellectual foundation was laid over decades by scientists who were initially ignored or disbelieved. Katalin Karikó spent years at the University of Pennsylvania arguing that mRNA could be a therapeutic tool, facing scepticism, funding cuts, and a demotion before her work was vindicated. The crucial breakthrough came in 2005, when she and Drew Weissman discovered that incorporating modified nucleosides — specifically pseudouridine — into synthetic mRNA eliminated the immune response that synthetic mRNA normally triggered, allowing it to be taken up and translated without being immediately destroyed. This discovery, which earned Karikó and Weissman the 2023 Nobel Prize in Physiology or Medicine, was the key that unlocked practical mRNA medicine.

The COVID-19 pandemic provided the first proof of concept at scale. The Pfizer-BioNTech and Moderna vaccines, developed with unprecedented speed using mRNA technology that had been in development for years, demonstrated that mRNA could be safely and effectively delivered to billions of people. Their success transformed the field’s ambitions entirely.

A June 2026 review in Nature Reviews Drug Discovery — “Towards mRNA therapeutics 2.0” — surveyed a decade of clinical trials and identified the key frontiers: enzyme replacement therapies for rare diseases, cancer immunotherapies, genome-modifying therapies using mRNA-encoded base editors or prime editors, and immune cell reprogramming therapies for cancer and autoimmune disease. Several innovative approaches have emerged: clinically tractable in vivo delivery systems, the development of completely immune-silent mRNA–vehicle formulations that allow repeated administration, and approaches for preferential delivery to specific tissues and cell types beyond the liver.

A December 2025 study in Nature Communications from researchers in Guangzhou demonstrated organ-selective mRNA delivery using a new class of lipid nanoparticles — addressing one of the field’s central limitations, that current LNP formulations primarily target the liver, restricting the range of diseases that can be treated. The team synthesised a library of meta/ortho/para-ionizable lipidoids and showed that specific structural variants could achieve efficient mRNA delivery to organs beyond the liver, including the brain — opening the possibility of mRNA therapies for neurological diseases.

In cancer, mRNA vaccines are showing results that are generating genuine excitement. A June 2026 study in Science Daily reported that an mRNA cancer vaccine developed by Elias Sayour’s group at the University of Florida — designed not to target specific tumour proteins but to broadly activate the immune system — wiped out tumours in mouse models when combined with checkpoint inhibitors, and in some cases eliminated tumours as a monotherapy.

This builds on a landmark first-in-human clinical trial from Sayour’s lab in which an mRNA vaccine reprogrammed the immune system to attack glioblastoma, one of the most aggressive and treatment-resistant brain tumours known. Earlier in 2026, a Nature study reported that mRNA vaccines against SARS-CoV-2 conferred improved survival among patients with advanced non-small-cell lung cancer or melanoma receiving immune checkpoint inhibitors, due to activation of systemic immunity that potentiated antitumour responses — an unexpected but mechanistically coherent finding that has added a new dimension to thinking about mRNA vaccine applications.

RNA Interference: Silencing Genes with Molecular Precision

In 1998, Andrew Fire and Craig Mello discovered that double-stranded RNA — RNA with two complementary strands — could silence specific genes in C. elegans with extraordinary potency. The silencing was sequence-specific: double-stranded RNA matching any given gene would knock down the expression of that gene dramatically. They called the phenomenon RNA interference, or RNAi. The 2006 Nobel Prize in Physiology or Medicine went to Fire and Mello for this discovery — one of the fastest Nobel Prize recognitions in the history of the award.

RNAi turned out to be a universal biological phenomenon, conserved across plants, animals, and fungi, that operates through a defined molecular pathway. Double-stranded RNA is processed by an enzyme called Dicer into small interfering RNA (siRNA) duplexes of approximately 21 nucleotides. These siRNA molecules are loaded into a multi-protein complex called RISC — the RNA-induced silencing complex. RISC uses one strand of the siRNA as a guide to find complementary sequences in target mRNAs and cleaves them, preventing their translation into protein. MicroRNAs, which were described above, work through a closely related pathway, using RISC to silence target mRNAs through imperfect complementarity rather than the perfect match required for siRNA cleavage.

The therapeutic potential of RNAi was immediately apparent: if you could deliver a synthetic siRNA matching any disease gene to the relevant cells, you could silence that gene with molecular precision. The challenge was delivery — naked siRNA is rapidly degraded in the bloodstream and does not efficiently enter cells. After years of intensive research into delivery strategies, the field reached a milestone in 2018 when the FDA approved patisiran (Onpattro) — the first siRNA drug — for the treatment of transthyretin amyloidosis, a progressive and fatal disease caused by the accumulation of misfolded transthyretin protein. Patisiran uses lipid nanoparticles to deliver siRNA targeting TTR mRNA to liver cells, silencing the gene and dramatically reducing transthyretin protein levels.

More siRNA drugs have followed, and the pipeline has expanded to include the liver, eye, and increasingly the central nervous system. Inclisiran, which uses a GalNAc-conjugated siRNA to silence PCSK9 in the liver — reducing LDL cholesterol levels by approximately 50% with just two injections per year — is approved in multiple countries and is one of the most promising cardiovascular therapeutics in recent years. The connection between this approach and the gene editing pipeline is direct: where CRISPR permanently edits the PCSK9 gene, inclisiran suppresses it reversibly through RNA interference. For the full story of how CRISPR and gene editing are changing medicine, see our article on what is CRISPR? the gene editing revolution that is rewriting human medicine.

RNA in Epigenetics: The Regulator of Regulators

RNA and epigenetics are more deeply intertwined than is often appreciated. The non-coding RNAs that regulate genome organisation — lncRNAs, small interfering RNAs derived from repetitive elements, and PIWI-interacting RNAs (piRNAs) — are among the primary mechanisms through which the epigenome is established and maintained.

PIWI-interacting RNAs are a class of small non-coding RNAs, 24 to 31 nucleotides long, expressed primarily in the germline — the egg and sperm cells — where they silence transposable elements: the “jumping genes” that make up approximately half the human genome and would, if left unsilenced, insert themselves into random locations in the genome and potentially disrupt gene function. piRNAs silence these transposable elements through a combination of RNA interference and DNA methylation, protecting genome integrity in the cells that pass genetic information to the next generation.

The RNA component of the Polycomb repressive complex 2 — one of the major chromatin-remodelling complexes that silences developmental genes — appears to be required for its targeting to specific genomic locations, with lncRNAs acting as scaffolds that recruit the complex to the genes it needs to silence. The relationship between lncRNAs and chromatin modification is one of the most active areas of current epigenomics research. For a full account of how epigenetics works and what it means for health and inheritance, see our article on epigenetics: how your environment shapes the way your genes work.

RNA as Biomarker and Diagnostic Tool

RNA’s dynamic nature — the fact that it reflects the current activity of the genome rather than its static sequence — makes it an ideal diagnostic tool. The transcriptome: the complete set of RNA molecules expressed in a cell or tissue at a given moment, is a readout of cellular state with extraordinary information content.

Single-cell RNA sequencing (scRNA-seq), developed and rapidly refined in the 2010s, can now measure the transcriptome of thousands or millions of individual cells simultaneously, generating maps of cell type and cell state at single-cell resolution. The Human Cell Atlas project — an international effort to create a reference map of every cell type in the human body using scRNA-seq and related technologies — has already characterised millions of cells from dozens of organs and tissues, discovering new cell types and revealing previously unknown cellular diversity in every organ examined.

Cell-free RNA in blood and other body fluids — including fragments of mRNA, miRNA, and circRNA — can be detected and quantified by liquid biopsy, providing non-invasive windows into tissue-specific gene expression. Specific miRNA profiles in blood can indicate the presence of certain cancers before symptoms appear. The stability of circular RNAs makes them particularly attractive as liquid biopsy biomarkers for diseases including Alzheimer’s disease, where circRNA profiles in cerebrospinal fluid may reflect brain-specific gene expression changes.

The connection between RNA biomarkers and the broader field of genetics research is direct. AlphaGenome — DeepMind’s AI system for predicting regulatory genome function — generates predictions of RNA expression levels across cell types as one of its primary outputs, connecting the sequence of the genome to the transcriptome it produces. For the full story of what AlphaGenome can do, see our article on decoding the dark DNA: how DeepMind’s AlphaGenome is revolutionising genetic research.

What Comes Next: The RNA Therapies of the 2030s

The RNA therapeutic landscape in 2026 is generating a pipeline of approaches that would have seemed like science fiction a decade ago.

Circular RNA therapies are entering early clinical development. The covalently closed circular structure of circRNA makes it extraordinarily resistant to degradation — potentially producing longer-lasting protein expression from a single dose than conventional linear mRNA. Olink Therapeutics and several academic groups are developing circular mRNA platforms for therapeutic protein replacement. The integration of single-cell and spatial transcriptomics with targeted RNA-protein crosslinking is also sharpening causal maps of non-coding RNA activity in intact tissue — connecting the presence of specific lncRNAs and circRNAs to specific phenotypes in specific cell types at specific locations within organs.

RNA base editing — using adenosine deaminase acting on RNA (ADAR) enzymes, either endogenous or delivered therapeutically, to make specific A-to-I edits in RNA rather than in DNA — offers a form of genetic correction that is inherently transient and reversible. Unlike DNA base editing, RNA base editing does not permanently alter the genome: the edited RNA is eventually degraded and replaced by transcripts from the unchanged DNA. This transience is both a limitation and a safety advantage, depending on the application. Wave Life Sciences and Korro Bio are developing ADAR-based RNA editing approaches for liver and other organ diseases.

The broader vision — for RNA therapy to become a platform technology capable of addressing virtually any genetic disease by modulating RNA rather than editing DNA — is now within sight. The tools of RNA medicine have progressed from the siRNA drugs that reached the clinic in 2018 to a spectrum of modalities that includes mRNA, siRNA, antisense oligonucleotides, circular RNA, RNA base editing, and RNA-guided protein systems. Each addresses different disease biology and different delivery challenges. Together, they represent the most productive therapeutic platform since the development of monoclonal antibodies in the 1980s.

The connection between this therapeutic revolution and the foundational genetics described in our article on what is DNA? is direct and profound. DNA carries the instructions. RNA reads them, executes them, regulates them, and — it now turns out — can be targeted to fix them when they go wrong. The molecule that was once dismissed as a molecular middleman has turned out to be the most therapeutically accessible layer of the genome. RNA did not just turn out to be more important than we thought. It turned out to be central to almost everything.

Frequently Asked Questions

What is RNA and how is it different from DNA?

RNA (ribonucleic acid) is a single-stranded nucleic acid closely related to DNA. The key chemical differences are that RNA uses ribose sugar instead of deoxyribose, and uracil instead of thymine. RNA’s single-stranded nature allows it to fold into complex three-dimensional structures that enable it to perform both informational and catalytic functions — something DNA cannot do. RNA is generally shorter-lived than DNA, making it suited for dynamic, responsive gene regulation rather than long-term information storage.

What does RNA do in a cell?

RNA performs a remarkable range of functions. Messenger RNA (mRNA) carries genetic instructions from DNA to ribosomes for protein synthesis. Ribosomal RNA (rRNA) forms the catalytic core of the ribosome. Transfer RNA (tRNA) delivers amino acids during protein synthesis. MicroRNAs and siRNAs regulate gene expression by targeting specific mRNAs for silencing. Long non-coding RNAs regulate chromatin organisation and coordinate gene expression programmes. Circular RNAs act as regulatory molecules with exceptional stability. Together, these RNA types orchestrate virtually every aspect of cellular biology.

What is the RNA world hypothesis?

The RNA world hypothesis proposes that RNA, not DNA, was the original molecule of life on Earth. Before the current system of DNA, RNA, and proteins existed, RNA molecules capable of both storing genetic information and catalysing chemical reactions are thought to have been the first self-replicating molecules. The hypothesis is supported by the discovery that the ribosome is a ribozyme, by the nucleotide structure of essential metabolic cofactors, and by laboratory experiments demonstrating RNA-based self-replication and Darwinian evolution.

What are mRNA vaccines and how do they work?

mRNA vaccines deliver synthetic messenger RNA encoding a specific antigen — typically a viral protein — into cells, where it is translated into the antigen protein. The immune system recognises the antigen and develops an immune response and memory, conferring protection against the pathogen. The mRNA is degraded by normal cellular mechanisms after use, leaving no permanent genetic changes. The COVID-19 vaccines developed by Pfizer-BioNTech and Moderna used this technology, and it is now being applied to cancer, rare diseases, and other conditions.

What is RNA interference?

RNA interference (RNAi) is a cellular mechanism, discovered in 1998 and recognised with the 2006 Nobel Prize, in which small RNA molecules guide the sequence-specific silencing of target genes. Double-stranded RNA matching a target gene is processed into small interfering RNAs (siRNAs) that direct destruction of the corresponding mRNA. RNAi is a universal biological phenomenon found across plants, animals, and fungi, and has been developed into a class of therapeutic drugs that can silence virtually any gene with molecular precision.

What are long non-coding RNAs?

Long non-coding RNAs (lncRNAs) are RNA molecules longer than 200 nucleotides that do not encode proteins. The human genome encodes over 50,000 lncRNA genes. Despite initially being dismissed as transcriptional noise, lncRNAs are now known to play essential roles in regulating chromatin organisation, recruiting epigenetic modifiers to specific genomic locations, and coordinating large-scale gene expression programmes. Their disruption is associated with cancer, cardiovascular disease, and neurological disorders.

Sources

About the Author

Baryon is the founder and editor of Web News For Us. Driven by a deep fascination with the biggest unanswered questions in science — from quantum physics and cosmology to the nature of consciousness and the genetic code written into every living cell — he has spent years studying modern physics, biology, and the history of scientific thought. He covers Science & AI, Space, Genetics & Research, and the timeless wisdom of history’s greatest thinkers and mystics.

If you have ever looked at the night sky and felt that pull to understand what is out there or wondered about an entire universe coiled inside your genes, you are in the right place.